专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US06395753B1 Cyclic amine compounds and pharmaceutical composition containing the same 有权
标题翻译：环胺化合物和含有其的药物组合物
公开(公告)号：US06395753B1
公开(公告)日：2002-05-28
申请号：US09941684
申请日：2001-08-30
申请人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani , Masao Ohkuchi
发明人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani , Masao Ohkuchi
IPC分类号： A61K314545
CPC分类号： C07D401/06 , A61K31/4545 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/14
摘要： A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 and W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 each independently represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl group; and l, m and n each represents a number of 0 or 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.
摘要翻译：由以下通式（1）表示的环胺化合物：其中，R1，R2和R3各自独立地表示氢原子或烷氧基; W1和W2各自独立地表示N或CH; X表示O，NR4，CONR4或 NR4CO; R4各自独立地表示氢原子，或烷基，芳基，杂芳基，芳烷基或杂芳烷基; 和l，m和n各自表示0或1的数，其盐和其水合物。这些化合物对细胞粘附和细胞浸润都具有抑制作用，并且可用作抗哮喘剂，抗过敏剂，抗风湿剂，抗动脉硬化剂，抗炎剂，抗干燥素综合征剂等。

32. 发明授权

US4668582A Thin film EL panel 失效
标题翻译：薄膜EL面板
公开(公告)号：US4668582A
公开(公告)日：1987-05-26
申请号：US713597
申请日：1985-03-19
申请人： Tomizo Matsuoka , Masahiro Nishikawa , Yosuke Fujita , Atsushi Abe , Tsuneharu Nitta
发明人： Tomizo Matsuoka , Masahiro Nishikawa , Yosuke Fujita , Atsushi Abe , Tsuneharu Nitta
IPC分类号： C23C14/08 , C23C28/00 , H05B33/22 , B32B9/00 , B32B19/00 , H01J1/62 , H01J63/04
CPC分类号： C23C14/08 , C23C28/00 , H05B33/22 , Y10S428/917
摘要： New black color insulator thin films comprising Pr oxide, composite oxides of Pr-Mn, Pr-Ni, Pr-Co or Mn oxide are used to constitute at least one part or all parts of interface film between a phosphor film and a back electrode film of an AC thin film EL panel; and the panel with such a high contrast as 5:1 even at an illumination of 400 lux has been obtained.
摘要翻译：包括Pr氧化物，Pr-Mn，Pr-Ni，Pr-Co或Mn氧化物的复合氧化物的新型黑色绝缘体薄膜用于构成荧光体膜和背面电极膜之间的界面膜的至少一部分或全部部分的AC薄膜EL面板; 并且已经获得了即使在400勒克司的照明下具有5:1的如此高的对比度的面板。

33. 发明授权

US4395440A Method of and apparatus for manufacturing ultrafine particle film 失效
标题翻译：超细颗粒膜的制造方法和设备
公开(公告)号：US4395440A
公开(公告)日：1983-07-26
申请号：US309088
申请日：1981-10-06
申请人： Atsushi Abe , Hisahito Ogawa , Masahiro Nishikawa
发明人： Atsushi Abe , Hisahito Ogawa , Masahiro Nishikawa
IPC分类号： C23C14/24 , C23C14/32 , B05D1/12 , C23C11/00
CPC分类号： C23C14/32 , C23C14/24
摘要： A method and apparatus for manufacturing an ultrafine particle film which has great practical utility when deposited on an appropriate substrate. The particle film is produced from various ultrafine particles of, for example, metals, oxides, nitrides and carbides, and is produced uniformly, effectively and efficiently with a high degree of reproducibility. According to a first method, an atmosphere at a gas of a reduced pressure is formed in a vessel, and a forced flow of the gas is formed unidirectionally from an evaporation source to the substrate, so that the evaporated matters from the evaporation source are forced to move together with the forced flow of the gas, so that ultrafine particles which are formed through interaction between the evaporated matters and the gas deposited on the substrate thereby forming the ultrafine particle film. According to a second method, the evaporation source is disposed within a vessel of having a reduced gas pressure as well as a cylinder surrounded by a high-frequency coil. As the coil is energized, the gas in the cylinder is excited. The evaporated matters are forced to flow through the excited gas atmosphere so that ultrafine particles formed by an interaction between the evaporated matters and the excited gas are deposited on the substrate thereby forming the ultrafine particle layer. A third method is a combination of the first and second methods.
摘要翻译：一种用于制造超细颗粒膜的方法和装置，其在沉积在合适的基底上时具有很大的实用性。颗粒膜由各种例如金属，氧化物，氮化物和碳化物的超微粒子制成，以高再现性均匀，有效且高效地制造。根据第一种方法，在容器中形成减压气体的气氛，从蒸发源向基板单向形成气体的强制流动，使来自蒸发源的蒸发物质被迫与气体的强制流动一起移动，使得通过蒸发的物质和沉积在基底上的气体之间的相互作用而形成的超细颗粒，从而形成超微粒子膜。根据第二种方法，蒸发源设置在具有降低的气体压力的容器中，以及由高频线圈包围的圆筒。当线圈通电时，气缸中的气体被激发。蒸发的物质被迫流过激发的气体气氛，使得通过蒸发物质和被激发气体之间的相互作用形成的超细颗粒沉积在基底上，从而形成超微粒子层。第三种方法是第一种和第二种方法的组合。

34. 发明申请

US20060167058A1 PPAR-activating compound 失效
标题翻译： PPAR活化化合物
公开(公告)号：US20060167058A1
公开(公告)日：2006-07-27
申请号：US11335669
申请日：2006-01-20
申请人： Yukiyoshi Yamazaki , Tsutomu Toma , Masahiro Nishikawa , Hajime Yamada , Hidefumi Ozawa , Ayumu Okuda , Kazutoyo Abe
发明人： Yukiyoshi Yamazaki , Tsutomu Toma , Masahiro Nishikawa , Hajime Yamada , Hidefumi Ozawa , Ayumu Okuda , Kazutoyo Abe
IPC分类号： A61K31/4439 , A61K31/428 , A61K31/423 , A61K31/4184
CPC分类号： C07D263/58
摘要： The present invention provides a compound selectively activating PPARα, which is useful as a medicament. The present invention is specifically directed to a benzoic acid derivative represented by the following general formula (1): wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a carboxy-alkyl group; X represents an oxygen atom, an NH group, or an S(O)n group (wherein n represents an integer of 0, 1, or 2); and m represents an integer from 2 to 8; or a salt thereof. The present invention also provides a medicament comprising the benzoic acid derivative or the salt thereof as an active ingredient.
摘要翻译：本发明提供选择性活化PPARα的化合物，其可用作药物。本发明具体涉及由以下通式（1）表示的苯甲酸衍生物：其中A表示氧原子，氮原子或硫原子; R表示氢原子，烷基，烯基，炔基，环烷基，环烷基 - 烷基，芳基，芳基 - 烷基，芳氧基 - 烷基，吡啶基 - 烷基，烷氧基羰基 - 烷基或羧基 - 烷基; X表示氧原子，NH基或S（O）n N（其中n表示0,1或2的整数）; m表示2〜8的整数，或其盐。本发明还提供了包含苯甲酸衍生物或其盐作为活性成分的药物。

35. 发明授权

US06911469B2 Sulfonamide compounds and pharmaceutical use thereof 失效
标题翻译：磺酰胺化合物及其药物用途
公开(公告)号：US06911469B2
公开(公告)日：2005-06-28
申请号：US10047093
申请日：2002-01-17
申请人： Hiroshi Kayakiri , Yoshito Abe , Hitoshi Hamashima , Hitoshi Sawada , Tsuyoshi Mizutani , Teruo Oku , Noritsugu Yamasaki , Osamu Onomura , Masahiro Nishikawa , Takahiro Hiramura , Takafumi Imoto
发明人： Hiroshi Kayakiri , Yoshito Abe , Hitoshi Hamashima , Hitoshi Sawada , Tsuyoshi Mizutani , Teruo Oku , Noritsugu Yamasaki , Osamu Onomura , Masahiro Nishikawa , Takahiro Hiramura , Takafumi Imoto
IPC分类号： G06Q50/10 , A61K20060101 , A61K31/381 , A63B69/36 , C07D20060101 , C07D215/48 , C07D231/56 , C07D239/96 , C07D241/52 , C07D249/18 , C07D307/79 , C07D333/54 , C07D333/56 , C07D333/62 , C07D405/12 , C07D409/12 , C07D471/04 , C07D487/04 , C07D495/04 , C07F20060101 , A61K31/34
CPC分类号： C07D241/52 , C07D215/48 , C07D231/56 , C07D239/96 , C07D249/18 , C07D307/79 , C07D333/54 , C07D333/62 , C07D405/12 , C07D409/12 , C07D471/04 , C07D487/04 , C07D495/04
摘要： A sulfonamide compound of the formula (I): R1—SO2NHCO—A—X—R2 (I) wherein R1 is alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.
摘要翻译：式（I）的磺酰胺化合物：<？in-line-formula description =“In-line Formulas”end =“lead”→> R 2 NHCO-AXR 2（I）<？in-line-formula description =“In-line Formulas”end =“tail”？>其中R 1是烷基，烯基，炔基等; A是任选取代的杂多环基团，除了苯并咪唑基，吲哚基，4,7-二氢苯并咪唑啉-2,3-二氢苯并恶嗪基; X是亚烷基，氧杂，氧杂（低级）亚烷基等; 和R 2是任选取代的芳基，取代的联苯基等，其盐和包含它们的药物组合物。磺胺类化合物可以基于其血糖降低活性，cGMP-PDE（特别是PDE-V）抑制活性，平滑肌松弛活性，支气管扩张活性，血管舒张活性，平滑肌细胞抑制活性，以及抗过敏活性。

36. 发明授权

US06703410B1 Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide 失效
标题翻译： 3-（2,4-二氯苄基）-2-甲基 - （戊基磺酰基）-3H-苯并咪唑-5-甲酰胺的晶体形式
公开(公告)号：US06703410B1
公开(公告)日：2004-03-09
申请号：US09831082
申请日：2001-09-13
申请人： Yoshiyuki Murai , Noritsugu Yamasaki , Takafumi Imoto , Masahiro Nishikawa , Kunihiko Dohtsu
发明人： Yoshiyuki Murai , Noritsugu Yamasaki , Takafumi Imoto , Masahiro Nishikawa , Kunihiko Dohtsu
IPC分类号： A61K314184
CPC分类号： A61K31/415 , A61K31/404 , C07D209/08 , C07D209/10 , C07D235/08
摘要： 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide, a compound having hypoglycemic activity or PDE5 inhibitory effect, has three forms of crystal forms that are distinguishable by their X-ray powder diffraction values. The most crystallographically stable crystal form is useful as a drug substance for medicines. Another crystal form can be purified efficiently by crystallization, since it forms larger crystals and can be very easily isolated by filtration. Thus this crystal form is useful for purifying 3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carboxamide.
摘要翻译： 3-（2,4-二氯苄基）-2-甲基-N-（戊基磺酰基）-3H-苯并咪唑-5-甲酰胺，具有降血糖活性或PDE5抑制作用的化合物具有三种形式，可通过其X 射线粉末衍射值。最具晶体稳定性的晶体形式可用作药物的药物。通过结晶可以有效地提纯另一种晶体，因为它形成较大的晶体，可以通过过滤非常容易地分离。因此，这种晶形可用于纯化3-（2,4-二氯苄基）-2-甲基-N-（戊基磺酰基）-3H-苯并咪唑-5-甲酰胺。

37. 发明授权

US06552188B2 Unsymmetrical cyclic diamine compound 失效
标题翻译：不对称环状二胺化合物
公开(公告)号：US06552188B2
公开(公告)日：2003-04-22
申请号：US09893699
申请日：2001-06-29
申请人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani
发明人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani
IPC分类号： A61K31496
CPC分类号： C07D213/81 , C07D213/36 , C07D213/82 , C07D401/12
摘要： Cyclic diamine compounds of formula (1) are disclosed: wherein A is (CH2)n, (CH2)n—CH═CH, CO—(CH2)n or CO—(CH2)n—CH═CH, in which n is a number of 0 to 3; Z represents a formula (2) or (3): in which R1, R2, R4, R5 and R6 are individually a hydrogen atom, alkyl group, alkoxy group, halogen atom or nitro group; R3is a hydrogen atom, alkyl group, alkoxy group, halogen atom, nitro group, naphthyl group, or phenyl group which may be substituted by 1 to 3 substituents selected from the group consisting of alkyl groups, alkoxy groups, halogen atoms, a nitro group and a phenyl group; and X and Y are individually CH or a nitrogen atom; and m is 1 or 2; an acid-addition salt thereof, or a hydrate thereof, and a medicine containing such a compound.
摘要翻译：公开了式（1）的环二胺化合物：其中A是（CH 2）n，（CH 2）n -CH = CH，CO-（CH 2）n或CO-（CH 2）n -CH = CH，其中n是数字0到3; Z表示式（2）或（3）：其中R1，R2，R4，R5和R6分别为氢原子，烷基，烷氧基，卤素原子或硝基; R3是氢原子，烷基，烷氧基，卤素原子，硝基，萘基或可以被1〜3个选自烷基，烷氧基，卤原子，硝基的取代基取代的苯基和苯基; X和Y分别是CH或氮原子; m为1或2;其酸加成盐或其水合物，以及含有这种化合物的药物。

38. 发明授权

US06498169B1 Cyclic amine compounds and pharmaceutical composition containing the same 有权
标题翻译：环胺化合物和含有其的药物组合物
公开(公告)号：US06498169B1
公开(公告)日：2002-12-24
申请号：US09983928
申请日：2001-10-26
申请人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani , Masao Ohkuchi
发明人： Tatsuhiko Kodama , Masahiro Tamura , Toshiaki Oda , Yukiyoshi Yamazaki , Masahiro Nishikawa , Shunji Takemura , Takeshi Doi , Yoshinori Kyotani , Masao Ohkuchi
IPC分类号： A61K314545
CPC分类号： C07D401/06 , A61K31/4545 , C07D211/58 , C07D401/12 , C07D401/14 , C07D403/14
摘要： A cyclic amine compound represented by the following general formula (1): wherein, R1, R2 and R3 each independently represent a hydrogen atom or an alkoxy group; W1 an W2 each independently represent N or CH; X represents O, NR4, CONR4 or NR4CO; R4 each independently represents a hydrogen atom, or an alkyl, aryl, heteroaryl, aralkyl, or heteroalkyl group; and l, m and n each represents a number of 0 to 1, a salt thereof and a hydrate thereof are provided. These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.
摘要翻译：由以下通式（1）表示的环胺化合物：其中，R 1，R 2和R 3各自独立地表示氢原子或烷氧基; W 1，W 2各自独立地表示N或CH; X表示O，NR 4，CONR 4或 NR4CO; R4各自独立地表示氢原子，或烷基，芳基，杂芳基，芳烷基或杂烷基; 和l，m和n各自表示0至1的数，其盐和其水合物。这些化合物对细胞粘附和细胞浸润均具有抑制作用，可用作抗哮喘剂，抗过敏剂，抗风湿剂，抗动脉硬化剂，抗炎剂，抗干燥素综合征剂等。

39. 发明授权

US6031113A Method of producing 4-hydroxy-2-pyrrolidinone and method of purifying the same 失效
公开(公告)号：US6031113A
公开(公告)日：2000-02-29
申请号：US318302
申请日：1999-05-25
申请人： Masahiro Nishikawa
发明人： Masahiro Nishikawa
IPC分类号： B01J31/02 , C07B61/00 , C07D207/26 , C07D207/273 , C07D207/12
CPC分类号： C07D207/273
摘要： 4-Hydroxy-2-pyrrolidinone which is useful as a raw material of drugs can be produced rapidly and highly selectively in a high yield from an optically active or recemic 4-amino-3-hydroxybutylic acid derivative or a 4-azido-3-hydroxybutyric acid derivative by adding a base catalyst to the reaction system. 4-Hydroxy-2-pyrrolidinone having a high optical purity can be obtained by carrying out recrystallization of optically active 4-hydroxy-2-pyrrolidinone without using a poor solvent.

40. 发明授权

US5476931A Process for preparing 3-deoxy-B-D-threo-pentofuranosyl nucleosides 失效
标题翻译：制备3-脱氧-B-D-苏 - 呋喃鸟苷的方法
公开(公告)号：US5476931A
公开(公告)日：1995-12-19
申请号：US862174
申请日：1992-04-02
申请人： Hiroyoshi Kuzuhara , Masajiro Kawana , Noritsugu Yamasaki , Masahiro Nishikawa
发明人： Hiroyoshi Kuzuhara , Masajiro Kawana , Noritsugu Yamasaki , Masahiro Nishikawa
IPC分类号： C07D405/04 , C07D473/00 , C07H19/06 , C07H19/16 , C07H1/00
CPC分类号： C07D473/00 , C07D405/04 , C07H19/06 , C07H19/16 , Y02P20/55
摘要： A process for preparing 3-deoxy-.beta.-D-threo-pentofuransyl nucleosides having the formula (II') shown below: ##STR1## wherein B is a purine, pyrimidine, a protected purine or a protected pyrimidine, andR.sup.4 is a hydroxyl protecting group;comprising treating a compound of formula (I'): ##STR2## wherein B is a purine, a protected purine, a pyrimidine or a protected pyrimidine;R.sup.1 is pivaloyl, tosyl, dimethoxytrityl, benzoyl, or hydroxyl;R.sup.2 is mesyl, triflate, or tosyl; andR.sup.3 is pivaloyl, tosyl, dimethoxytrityl, benzoyl, and hydroxyl with a base--an alkaki metal lower alkoxide, an alkaline earth metal lower alkoxide, sodium hydroxide, or potassium hydroxide--along with a reducing agent--an alkali metal borohydride, an alkaline earth metal borohydride, tetraalkylammonium borohydride in an alcohol solvent at a temperature of from 0.degree. C. to 100.degree. C. for five minutes to two hours. The resulting 3'-deoxy-.beta.-D-threo-pentofuranosyl nucleosides are antiviral.
摘要翻译：具有下式的式（II'）的3-脱氧-β-D-呋喃戊呋酰基核苷的方法：其中B是嘌呤，嘧啶，被保护的嘌呤或被保护的嘧啶，和 R4是羟基保护基; 包括处理式（I'）的化合物：嘌呤，嘧啶或被保护的嘧啶; R1是新戊酰基，甲苯磺酰基，二甲氧基三苯甲基，苯甲酰基或羟基; R2是甲磺酰，三氟甲磺酸酯或甲苯磺酰基; 和R3是新戊酰基，甲苯磺酰基，二甲氧基三苯甲基，苯甲酰基和羟基，与碱金属低级醇盐，碱土金属低级醇盐，氢氧化钠或氢氧化钾一起，还原剂 - 碱金属硼氢化物，碱在0℃至100℃的温度下，在醇溶剂中将硼氢化四烷基铵硼氢化物，四烷基铵硼氢化物处理5分钟至2小时。所得的3'-脱氧-β-D-苏氨呋喃糖基核苷是抗病毒的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式